Background Afaitnib shows anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failing to first era EGFR-TKI and chemotherapy. group (mutation may be the most common system of acquired level of resistance to EGFR-TKI, accounting for approximately 50C60?% of sufferers who created disease development after EGFR TKI [8C10]. Afatinib, thought to be second-generation EGFR-TKI, can be… Continue reading Background Afaitnib shows anti-tumor activity against metastatic EGFR-mutated NSCLC after prior